Table 3.
Impact of AEs on daily activities and work and need to receive medical care 1 month and 14 weeks after having received the second dose of the heterologous ChAdOx1/BNT162b2 vaccination compared with homologous BNT162b2 regimen. Foggia, Italy, 15 June−30 October 2021.
| Individuals who received heterologous ChAdOx1/BNT162b2 vaccination (n = 74) |
Individuals who received homologous BNT162b2 vaccination (n = 65) |
Univariate analysis |
|||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | Odds Ratio (95% CI) | X2 | p | |
| 1 month apart | |||||||
| Inability to normal daily activities (yes) | 2 | 2.70 | 2 | 3.08 | 0.875 (0.062–12.04) | 0.02 | .6398 |
| Inability to work (yes) | 2 | 2.70 | 2 | 3.08 | 0.875 (0.062–12.04) | 0.02 | .6398 |
| Need to receive medical care (yes) | 1 | 1.35 | 1 | 1.54 | |||
| 14 weeks apart | |||||||
| Inability to normal daily activities (yes) | 3 | 4.05 | 0 | 0.00 | - | ||
| Inability to work (yes) | 3 | 4.05 | 0 | 0.00 | - | ||
| Need to receive medical care (yes) | 2 | 2.70 | 1 | 1.54 | - | ||
n, number of participants in the group; 95% CI, 95% confidence interval.